REMARKS

Applicants respectfully request the Examiner to reconsider and withdraw the outstanding rejections in view of the foregoing amendments and the following remarks.

Interview

The undersigned initially wishes to thank Examiner Solola for the courtesies extended during the personal interview conducted for this application on October 10, 2002. The Interview Summary provided by Examiner Solola accurately reflects the discussions held which are also reflected in the Remarks below.

Status of the Claims

Claims 1- 48 are pending, with claim 1 being independent. Without conceding the propriety of the rejections, claims 1, 6-20, 25, 33-41, 46, and 47 have been amended to even more clearly recite and distinctly claim Applicants' invention and to pursue an early allowance. Support for the amendments can be found in the original claims, as well as throughout the specification. Therefore, no new matter has been added.

Applicants also would like to thank the Examiner for indicating that there is allowable subject matter.

Claim Rejections under 35 U.S.C. § 112

Claims 46-48 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite. Applicants have amended claims 46 and 47, thus rendering the rejection moot.

Election/Restriction

The Examiner has deemed the previous restriction proper and, therefore, made it final. Applicants maintain their previous traversal of the restriction requirement. Merely in order to expedite prosecution, Applicants have amended claim 1 to define that the ring formed by N and (Y) is a pyrrolidinyl, namely *n* is two and Y is $-CH_2-$.

Applicants maintain their previous traversal and also traverse this final restriction requirement and thus reserve the right to Petition the Commissioner requesting removal thereof.

Specifically, this restriction requirement necessitates the dissection of Applicant's claim 1 into 7 groups and, therefore, constitutes a refusal on the part of the Office to examine the claim that Applicants believe to best represent their invention. Applicants submit that it is improper for the Office to refuse to examine that which Applicants regard as their invention

unless the subject matter of the claims lacks unity of invention. Specifically, in *In re Weber*, 580 F.2d 455, 198 USPQ 328 (CCPA 1978), the court articulated the general proposition that:

> [A]n applicant has a right to have *each* claim examined on the merits. If an applicant submits a number of claims, it may well be that pursuant to a proper restriction requirement, those claims will be dispersed to a number of applications. Such action would not affect the right of the applicant eventually to have each of the claims examined in the form he considers to best define his invention. If, however, a single claim is required to be divided up and presented in several applications, that claim would never be considered on its merits. The totality of the resulting fragmentary claims would not necessarily be the equivalent of the original claim. Further, since the subgenera would be defined by the examiner rather than by the applicant, it is not inconceivable that a number of the fragments would not be described in the specification.

Id. at 331. (Emphasis in original).

In view of the above and similar case law, the Patent Office has set forth a general policy regarding restriction of Markush-type claims in MPEP 803.02. According to the general policy as articulated in the MPEP, "since the decisions in *In re Weber*, 580 F.2d 455, 198 USPQ 328 (CCPA 1978) and *In re Haas*, 580 F.2d 461, 198 USPQ 334, it is improper for the Office to refuse to examine that which applicants regard as their invention, unless the subject matter in a claim lacks unity of invention. *In re Harnish*, 631 F.2d 716, 206 USPQ 300 (CCPA 1980); and *Ex parte Hozumi*, 3 USPQ2d 1059 (Bd. Pat. App. & Int. 1984)." Unity of invention exists where compounds included within a Markush group (1) share a common utility and (2) share a substantial structural feature.

Accordingly, Applicants submit that it is improper for the Office to refuse to examine the presently claimed invention since the presently claimed subject matter clearly evidences unity of invention. With regard to a common utility, the compounds of the present invention are used for the treatment of a disease treatable by administration of a peptidyl deformylase inhibitor, in particular bacterial diseases. (Specification, page 6, lines 12-28; claims 47 and 48). With regard to a substantial structural feature, the compounds of the present invention all share a common backbone as defined by Formula (I), which includes a hydroxamic acid functionality at one terminus of the backbone linked by succinate functionality to a pyrrolidinyl ring at the other terminus. This recited structure provides a common structural backbone that is a substantial structural feature. This common structural backbone can readily be searched without serious burden.

Accordingly, Applicants respectfully submit that as unity of invention exists in the presently claimed compounds, it is improper for the Office to refuse to examine the invention as claimed.

Applicants reserve the right to file a divisional application covering the non-elected subject matter.

In addition to the above and as noted during the interview, Applicants are willing to file one or more divisional applications directed to the different embodiments of Y and *n* in order to provide a clear unity of invention for each embodiment of Y and *n*. Specifically, Applicants would be willing to file divisional applications for each combination of Y and each value of *n*.

Conclusion

Without conceding the propriety of the rejections, the claims have been amended, as provided above, to even more clearly recite and distinctly claim Applicant's invention and to pursue an early allowance.

In view of the foregoing remarks, reconsideration of the claims and allowance of the subject application is earnestly solicited. The Examiner is invited to contact the undersigned at the below-listed telephone number, if it is believed that prosecution of this application may be assisted thereby.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____
Lorna L. Tanner
Registration No. 50,782

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

Date: December 18, 2002

Attachment to Amendment

Marked Up Copy

1. (Amended) A compound of Formula (I):





wherein:

R_1 is hydrogen, halo, -OH, $-R_8OR_9$, $-R_9$, $-OR_9$, -SH, $-SR_9$, $-NH_2$, $-NHR_9$ $-NR_9R_{10}$, -NHC(=O)H, $-NR_9C(=O)H$, $-NHC(=O)R_9$, $-NR_9C(=O)R_{10}$, $-NHC(=O)NH_2$, $-NR_9C(=O)NH_2$, $-NHC(=O)NHR_9$, $-NHC(=O)NR_9R_{10}$, $-NR_9C(=O)NR_{9a}R_{10}$, $-NHC(=O)OR_9$, $-NR_9C(=O)OR_{10}$, $-NHS(=O)_2R_9$, $-NR_9S(=O)_2R_{10}$, $-NHS(=O)_2OR_9$, or $-NR_9S(=O)_2OR_{10}$ where R_8 is selected from the group consisting of $-C_1$-C_{12} alkylene, substituted alkylene, or heteroalkylene, -C_1-C_{12} alkenylene, substituted alkenylene, or heteroalkenylene, -C_1-C_{12} alkynylene, substituted alkynylene, or heteroalkynylene, and $-(C_1$-C_8 alkylene or substituted alkylene$)_{n1}$-(C_3-C_{12} arylene or heteroarylene)-(C_1-C_8 alkyl or substituted alkyl$)_{n2}$ where n1 and n2 are independently 0 or 1; and R_9, R_{9a} and R_{10} are independently selected from the group consisting of $-C_1$-C_{12} alkyl, substituted alkyl, or heteroalkyl, -C_1-C_{12} alkenyl, substituted alkenyl, or heteroalkenyl, -C_1-C_{12} alkynyl, substituted alkynyl, or heteroalkynyl, and $-(C_1$-C_8 alkyl or substituted alkyl$)_{n3}$-(C_3-C_{12} arylene or heteroarylene)-(C_1-C_8 alkyl or substituted alkyl$)_{n4}$ where n3 and n4 are independently 0 or 1;

R_2 is independently hydrogen or $-R_9$ wherein R_9 is as defined above;

R_3 is hydrogen, halo, $-R_{11}$, -OH, $-OR_{11}$, $-R_{12}OR_{11}$, -SH, $-SR_{11}$, $-NH_2$, $-NHR_{11}$, $-NR_{11}R_{13}$, -NHC(=O)H, $-NR_{11}C(=O)H$, $-NHC(=O)R_{11}$, $-NR_{11}C(=O)R_{13}$, $-NHC(=O)NH_2$, $-NR_{11}C(=O)NH_2$, $-NHC(=O)NHR_{11}$, $-NHC(=O)NR_{11}R_{13}$, $-NR_{11}C(=O)NR_{11a}R_{13}$, $-NHC(=O)OR_{11}$, $-NR_{11}C(=O)OR_{13}$, $-NHS(=O)_2R_{13}$, $-NR_{11}S(=O)_2R_{13}$, $-NHS(=O)_2OR_{11}$, or $-NR_{11}S(=O)_2OR_{13}$, where R_{12} is selected from the group consisting of $-C_1$-C_{12} alkylene,

substituted alkylene, or heteroalkylene, -C_1-C_{12} alkenylene, substituted alkenylene, or heteroalkenylene, -C_1-C_{12} alkynylene, substituted alkynylene, or heteroalkynylene, and –(C_1-C_8 alkylene or substituted alkylene)$_{n5}$-(C_3-C_{12} arylene or heteroarylene)-(C_1-C_8 alkyl or substituted alkyl)$_{n6}$ where n5 and n6 are independently 0 or 1; and R_{11}, R_{11a} and R_{13} are independently selected from the group consisting of –C_1-C_{12} alkyl, substituted alkyl, or heteroalkyl,

-C_1-C_{12} alkenyl, substituted alkenyl, or heteroalkenyl, -C_1-C_{12} alkynyl, substituted alkynyl, or heteroalkynyl, and –(C_1-C_8 alkyl or substituted alkyl)$_{n7}$-(C_3-C_{12} arylene or heteroarylene)-(C_1-C_8 alkyl or substituted alkyl)$_{n8}$ where n7 and n8 are independently 0 or 1;

R_4 is hydrogen or –R_{11} where –R_{11} is as defined above;

[n is an integer from 1 to 5;

zero or one Y is selected from the group consisting of –O-, -NR_{11}- where R_{11} is as defined above, and –S-, and all remaining Y are –CR_6R_7- where] R_6 and R_7 are each independently selected from the group consisting of hydrogen, -R_{14}, -OH, -OR_{14}, -SH, -SR_{14}, -NH_2, -NHR_{14}, -$NR_{14}R_{15}$, -C(=O)H, -C(=O)R_{14}, -C(=O)NH_2, -C(=O)NHR_{14}, -C(=O)$NR_{14}R_{15}$, -C(=O)OH, -C(=O)OR_{14}, -C(=O)SH, -C(=O)SR_{14}, -C(=O)CH_3, -C(=O)CH_2R_{14}, -C(=O)$CHR_{14}R_{15}$, -C(=O)$CR_{14}R_{15}R_{16}$, -C(=O)OCH_3, -C(=O)OCH_2R_{14}, -C(=O)$OCHR_{14}R_{15}$, -C(=O)$OCR_{14}R_{15}R_{16}$, -$S(=O)_2NH_2$, -$S(=O)_2NHR_{14}$, -$S(=O)_2NR_{14}R_{15}$, -NHC(=O)H, -$N(R_{14})$C(=O)H, -NHC(=O)R_{15}, -$N(R_{14})$C(=O)R_{15}, -NHC(=O)OR_{14}, -$NHS(=O)_2H$, -$N(R_{14})S(=O)_2H$, -$NHS(=O)_2OR_{15}$, -$N(R_{14})S(=O)_2OR_{15}$, -$N(H)S(=O)_2R_{15}$, -$N(R_{14})S(=O)_2R_{15}$ and where two vicinal R_6 or R_7 groups combine to form a substituted or unsubstituted –C_4-C_{10} cyclic alkyl, cyclic heteroalkyl, aryl or heteroaryl group where R_{14}, R_{15} and R_{16} are each independently selected from the group consisting of –C_1-C_{12} alkyl, substituted alkyl, or heteroalkyl,

-C_1-C_{12} alkenyl, substituted alkenyl, or heteroalkenyl, -C_1-C_{12} alkynyl, substituted alkynyl, or heteroalkynyl, alkoxy, and –(C_1-C_8 alkyl or substituted alkyl)$_{n9}$-(C_3-C_{12} arylene or heteroarylene)-(C_1-C_8 alkyl or substituted alkyl)$_{n10}$ where n9 and n10 are independently 0 or 1; or when R_{14} and R_{15} are attached to a nitrogen atom they can combine to form a substituted or unsubstituted –C_4-C_{10} cyclic alkyl, cyclic heteroalkyl, aryl or heteroaryl group; or a pharmaceutically acceptable salt thereof.

6. (Amended) The compound of Claim 5 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)$NR_{14}R_{15}$ where R_{14} and R_{15} are independently selected from the group consisting of hydrogen, -(C_1-C_{12}) alkyl, substituted alkyl, or heteroalkyl, -(C_1-C_{12}) alkenyl, substituted alkenyl, or heteroalkenyl, -(C_1-C_{12}) alkynyl, substituted alkynyl, or heteroalkynyl, alkoxy, and -(C_1-C_8 alkyl or substituted alkyl)$_{n9}$-(C_3-C_{12} arylene or heteroarylene)-(C_1-C_8 alkyl or substituted alkyl)$_{n10}$ where n9 and n10 are independently 0 or 1; or R_{14} and R_{15} combine to form a substituted or unsubstituted -(C_4-C_{10})cyclic alkyl, cyclic heteroalkyl, aryl or heteroaryl group.

7. (Amended) The compound of Claim 5 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)$NR_{14}R_{15}$ where R_{14} and R_{15} are each independently hydrogen or –(C_1-C_{12}) alkyl, alkoxy, aryl, heteroaryl or R_{14} and R_{15}, when attached to the same carbon, combine to form a cyclic heteroalkyl, aryl or heteroaryl group.

8. (Amended) The compound of Claim 5 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)NHR$_{15}$ where R_{15} is H or –(C_1-C_{12}) alkyl, aryl, or heteroaryl or -C(=O)N$R_{14}R_{15}$ where R_{14} and R_{15} form a substituted or unsubstituted -(C_4-C_{10})cyclic heteroalkyl.

9. (Amended) The compound of Claim 5 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is *n*-butylaminocarbonyl, *tert*-butylaminocarbonyl, benzylaminocarbonyl, 1,1-dimethylpropylaminocarbonyl, 2-(cyclohexen-1-yl)-ethylaminocarbonyl, indan-5-ylaminocarbonyl, 4,5-dimethylthiazol-2-ylaminocarbonyl, 4-phenoxyphenylaminocarbonyl, cyclopropylmethyl-aminocarbonyl, pyridin-2-ylaminocarbonyl, pyridin-3-ylaminocarbonyl, pyridin-4-ylmethylaminocarbonyl, morpholin-4-ylcarbonyl, 3,4-methylenedioxy-phenylaminocarbonyl, quinolin-3-ylaminocarbonyl, methylaminocarbonyl, 4-biphenylaminocarbonyl, 3-phenoxyphenylaminocarbonyl, 3,4-dichlorophenyl-aminocarbonyl, 4-*tert*-butylphenylaminocarbonyl, 4-*tert*-butylaminocarbonyl, indan-2-ylaminocarbonyl, 2,2-dimethylpropylaminocarbonyl, 4-phenylthiazol-2-ylaminocarbonyl, 5-phenylthiadiazol-2-ylaminocarbonyl, 5-ethylthiadiazol-3-ylaminocarbonyl, thiadiazol-2-ylaminocarbonyl, 3-

trifluoromethoxyphenyl-aminocarbonyl, 2,5-dimethylphenylaminocarbonyl, 2,5-dimethoxyphenylamino-carbonyl, 3,4-dichlorophenylaminocarbonyl, benzthiazol-2-ylaminocarbonyl, 3-phenoxyphenylaminocarbonyl, 2-hydroxybutylaminocarbonyl, 4-hydroxybutyl-aminocarbonyl, 1,4-benzodioxan-6-ylaminocarbonyl, isoquinolin-6-ylaminocarbonyl, methylaminocarbonyl, thiazol-2-ylaminocarbonyl, 4-methylthiazol-2-yl-aminocarbonyl, 3-methylbutyl-aminocarbonyl, *n*-pentylaminocarbonyl, cyclohexylaminocarbonyl, 5-methylthiazol-2-ylaminocarbonyl, 4-methylthiazol-2-yl-aminocarbonyl, 2,4-dimethoxyphenyl-aminocarbonyl, 3,4-methylenedioxyphen-5-yl-methylaminocarbonyl, allylaminocarbonyl, 2-methylallylaminocarbonyl, pyrrolidin-1-ylcarbonyl, ethylaminocarbonyl, phenylaminocarbonyl, indan-1-ylaminocarbonyl, 2-methoxyethylaminocarbonyl, indan-5-ylaminocarbonyl, 3,4-difluorophenyl-aminocarbonyl, 5-methylisoxazol-5-ylaminocarbonyl, 3-fluorophenylaminocarbonyl, 4-fluorophenylaminocarbonyl, *N*-methyl-*N*-phenylaminocarbonyl, 2-propylamino-carbonyl, 2-phenylpropylaminocarbonyl, *n*-propylaminocarbonyl, *N*-ethyl-*N*-(*n*-butyl)aminocarbonyl, benzylaminocarbonyl, thiazolidin-1-ylcarbonyl, piperazin-1-yl-carbonyl, piperidin-1-ylcarbonyl, azetidin-1-ylcarbonyl, homopiperdin-1-ylcarbonyl, pyrimidin-2-ylaminocarbonyl, 4-methylpiperazin-1-ylcarbonyl, 4-methylpyrimidin-2-ylaminocarbonyl, pyrimidin-4-ylaminocarbonyl, pyrazin-2-ylaminocarbonyl, imidazol-2-ylaminocarbonyl.

10. (Amended) The compound of Claim 5 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is piperidin-1-ylcarbonyl, azetidin-1-ylcarbonyl, ethylaminocarbonyl, phenylaminocarbonyl, pyrimidin-2-ylaminocarbonyl, or thiazol-2-ylaminocarbonyl,[; and] the stereochemistry at the C2 carbon atom of the pyrrolidine ring[, i.e., carbon carrying the R_7 group] is (*S*), and R_3 is *n*-butyl.

11. (Amended) The compound of Claim 5 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is $-C(=O)OR_{14}$ where R_{14} is hydrogen or $-(C_1-C_{12})$ alkyl, alkoxy, aryl, or heteroaryl.

12. (Amended) The compound of Claim 5 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)OR_{14} where R_{14} is alkyl[;] and the stereochemistry at the C_2 carbon atom of the pyrrolidine ring is (*S*).

13. (Amended) The compound of Claim 1 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)$NR_{14}R_{15}$ where R_{14} and R_{15} are independently selected from the group consisting of hydrogen, -(C_1-C_{12}) alkyl, substituted alkyl, or heteroalkyl, -(C_1-C_{12}) alkenyl, substituted alkenyl, or heteroalkenyl, -(C_1-C_{12}) alkynyl, substituted alkynyl, or heteroalkynyl, alkoxy, and -(C_1-C_8 alkyl or substituted alkyl)$_{n9}$-(C_3-C_{12} arylene or heteroarylene)-(C_1-C_8 alkyl or substituted alkyl)$_{n10}$ where n9 and n10 are independently 0 or 1; or R_{14} and R_{15} combine to form a substituted or unsubstituted -(C_4-C_{10})cyclic alkyl, cyclic heteroalkyl, aryl or heteroaryl group.

14. (Amended) The compound of Claim 1 wherein [the

group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)$NR_{14}R_{15}$ where R_{14} and R_{15} are each independently hydrogen or –(C_1-C_{12}) alkyl, alkoxy, aryl, heteroaryl or R_{14} and R_{15}, when attached to the same carbon, combine to form a cyclic heteroalkyl, aryl or heteroaryl group.

15. (Amended) The compound of Claim 1 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)NHR_{15} where R_{15} is H or –(C_1-C_{12}) alkyl, aryl, or heteroaryl or -C(=O)$NR_{14}R_{15}$ where R_{14} and R_{15} form a substituted or unsubstituted -(C_4-C_{10})cyclic heteroalkyl.

16. (Amended) The compound of Claim 1 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is *n*-butylaminocarbonyl, *tert*-butylaminocarbonyl, benzylaminocarbonyl, 1,1-dimethylpropylaminocarbonyl, 2-(cyclohexen-1-yl)-ethylaminocarbonyl, indan-5-ylaminocarbonyl, 4,5-dimethylthiazol-2-ylaminocarbonyl, 4-phenoxyphenyl-aminocarbonyl, cyclopropylmethyl-aminocarbonyl, pyridin-2-ylaminocarbonyl, pyridin-3-ylaminocarbonyl, pyridin-4-ylmethylaminocarbonyl, morpholin-4-ylcarbonyl, 3,4-methylenedioxy-phenylaminocarbonyl, quinolin-3-ylaminocarbonyl, methylaminocarbonyl, 4-biphenylaminocarbonyl, 3-phenoxyphenylaminocarbonyl, 3,4-dichlorophenyl-aminocarbonyl, 4-*tert*-butylphenylaminocarbonyl, 4-*tert*-butylaminocarbonyl, indan-2-ylaminocarbonyl, 2,2-dimethylpropylaminocarbonyl, 4-phenylthiazol-2-ylaminocarbonyl, 5-phenylthiadiazol-2-ylaminocarbonyl, 5-ethylthiadiazol-3-ylaminocarbonyl, thiadiazol-2-ylaminocarbonyl, 3-trifluoromethoxyphenyl-aminocarbonyl, 2,5-dimethylphenylaminocarbonyl, 2,5-dimethoxyphenylamino-carbonyl, 3,4-dichlorophenylaminocarbonyl, benzthiazol-2-ylaminocarbonyl, 3-phenoxyphenylaminocarbonyl, 2-hydroxybutylaminocarbonyl, 4-hydroxybutyl-aminocarbonyl, 1,4-benzodioxan-6-ylaminocarbonyl, isoquinolin-6-ylaminocarbonyl, methylaminocarbonyl, thiazol-2-ylaminocarbonyl, 4-methylthiazol-2-yl-aminocarbonyl, 3-methylbutyl-aminocarbonyl, *n*-pentylaminocarbonyl, cyclohexylaminocarbonyl, 5-methylthiazol-2-ylaminocarbonyl, 4-methylthiazol-2-yl-aminocarbonyl, 2,4-dimethoxyphenyl-aminocarbonyl, 3,4-methylenedioxyphen-5-yl-methylaminocarbonyl, allylaminocarbonyl, 2-methylallylaminocarbonyl, pyrrolidin-1-ylcarbonyl, ethylaminocarbonyl, phenylaminocarbonyl, indan-1-ylaminocarbonyl, 2-methoxyethylaminocarbonyl, indan-5-ylaminocarbonyl, 3,4-difluorophenyl-aminocarbonyl, 5-methylisoxazol-5-ylaminocarbonyl, 3-fluorophenylaminocarbonyl, 4-fluorophenylaminocarbonyl, *N*-methyl-*N*-phenylaminocarbonyl, 2-propylamino-carbonyl, 2-phenylpropylaminocarbonyl, *n*-propylaminocarbonyl, *N*-ethyl-*N*-(*n*-butyl)aminocarbonyl, benzylaminocarbonyl, thiazolidin-1-ylcarbonyl, piperazin-1-yl-carbonyl, piperidin-1-ylcarbonyl, azetidin-1-ylcarbonyl, homopiperdin-1-ylcarbonyl, pyrimidin-2-ylaminocarbonyl, 4-methylpiperazin-1-ylcarbonyl, 4-methylpyrimidin-2-ylaminocarbonyl, pyrimidin-4-ylaminocarbonyl, pyrazin-2-ylaminocarbonyl, imidazol-2-ylaminocarbonyl.

17. (Amended) The compound of Claim 1 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is piperidin-1-ylcarbonyl, azetidin-1-ylcarbonyl, ethylaminocarbonyl, phenylaminocarbonyl, pyrimidin-2-ylaminocarbonyl, or thiazol-2-ylaminocarbonyl[;] and the stereochemistry at the C2 carbon atom of the pyrrolidine ring[, i.e., carbon carrying the R_7 group] is (*S*).

18. (Amended) The compound of Claim 1 wherein [the

group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)OR_{14} where R_{14} is hydrogen or –(C_1-C_{12}) alkyl, alkoxy, aryl, or heteroaryl.

19. (Amended) The compound of Claim 1 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)OR_{14} where R_{14} is alkyl[;] and the stereochemistry at the C_2 carbon atom of the pyrrolidine ring is (*S*).

20. (Amended) The compound of <u>any one of Claims</u> [Claim] 13-19 wherein R_2 and R_4 are hydrogen.

25. (Amended) The compound of <u>any one of Claims</u> [Claim] 13-19 wherein R_1 is halo.

33. (Amended) The compound of Claim 31 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)$NR_{14}R_{15}$ where R_{14} and R_{15} are independently selected from the group consisting of hydrogen, -(C_1-C_{12}) alkyl, substituted alkyl, or heteroalkyl, -(C_1-C_{12}) alkenyl, substituted alkenyl, or heteroalkenyl, -(C_1-C_{12}) alkynyl, substituted alkynyl, or heteroalkynyl, alkoxy, and -(C_1-C_8 alkyl or substituted alkyl)$_{n9}$-(C_3-C_{12} arylene or heteroarylene)-(C_1-C_8 alkyl or substituted alkyl)$_{n10}$ where n9 and n10 are independently 0 or 1; or R_{14} and R_{15} combine to form a substituted or unsubstituted -(C_4-C_{10})cyclic alkyl, cyclic heteroalkyl, aryl or heteroaryl group.

34. (Amended) The compound of Claim 31 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)$NR_{14}R_{15}$ where R_{14} and R_{15} are each independently hydrogen or –(C_1-C_{12}) alkyl, alkoxy, aryl, heteroaryl or R_{14} and R_{15}, when attached to the same carbon, combine to form a cyclic heteroalkyl, aryl or heteroaryl group.

35. (Amended) The compound of Claim 31 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)NHR_{15} where R_{15} is H or –(C_1-C_{12}) alkyl, aryl, or heteroaryl or -C(=O)$NR_{14}R_{15}$ where R_{14} and R_{15} form a substituted or unsubstituted -(C_4-C_{10})cyclic heteroalkyl.

36. (Amended) The compound of Claim 31 wherein [the

group is a group of formula:



wherein:

n is 1; and]

R_7 is *n*-butylaminocarbonyl, *tert*-butylaminocarbonyl, benzylaminocarbonyl, 1,1-dimethylpropylaminocarbonyl, 2-(cyclohexen-1-yl)-ethylaminocarbonyl, indan-5-ylaminocarbonyl, 4,5-dimethylthiazol-2-ylaminocarbonyl, 4-phenoxyphenylaminocarbonyl, cyclopropylmethyl-aminocarbonyl, pyridin-2-ylaminocarbonyl, pyridin-3-ylaminocarbonyl, pyridin-4-ylmethylaminocarbonyl, morpholin-4-ylcarbonyl, 3,4-methylenedioxy-phenylaminocarbonyl, quinolin-3-ylaminocarbonyl, methylaminocarbonyl, 4-biphenylaminocarbonyl, 3-phenoxyphenylaminocarbonyl, 3,4-dichlorophenyl-aminocarbonyl, 4-*tert*-butylphenylaminocarbonyl, 4-*tert*-butylaminocarbonyl, indan-2-ylaminocarbonyl, 2,2-dimethylpropylaminocarbonyl, 4-phenylthiazol-2-ylaminocarbonyl, 5-phenylthiadiazol-2-ylaminocarbonyl, 5-ethylthiadiazol-3-ylaminocarbonyl, thiadiazol-2-ylaminocarbonyl, 3-trifluoromethoxyphenyl-aminocarbonyl, 2,5-dimethylphenylaminocarbonyl, 2,5-dimethoxyphenylamino-carbonyl, 3,4-dichlorophenylaminocarbonyl, benzthiazol-2-ylaminocarbonyl, 3-phenoxyphenylaminocarbonyl, 2-hydroxybutylaminocarbonyl, 4-hydroxybutyl-aminocarbonyl, 1,4-benzodioxan-6-ylaminocarbonyl, isoquinolin-6-ylaminocarbonyl, methylaminocarbonyl, thiazol-2-ylaminocarbonyl, 4-methylthiazol-2-yl-aminocarbonyl, 3-methylbutyl-aminocarbonyl, *n*-pentylaminocarbonyl, cyclohexylaminocarbonyl, 5-methylthiazol-2-ylaminocarbonyl, 4-methylthiazol-2-yl-aminocarbonyl, 2,4-dimethoxyphenyl-aminocarbonyl, 3,4-methylenedioxyphen-5-yl-methylaminocarbonyl, allylaminocarbonyl, 2-methylallylaminocarbonyl, pyrrolidin-1-ylcarbonyl, ethylaminocarbonyl, phenylaminocarbonyl, indan-1-ylaminocarbonyl, 2-methoxyethylaminocarbonyl, indan-5-ylaminocarbonyl, 3,4-difluorophenyl-aminocarbonyl, 5-methylisoxazol-5-ylaminocarbonyl, 3-fluorophenylaminocarbonyl, 4-fluorophenylaminocarbonyl, *N*-methyl-*N*-phenylaminocarbonyl, 2-propylamino-carbonyl, 2-phenylpropylaminocarbonyl, *n*-propylaminocarbonyl, *N*-ethyl-*N*-(*n*-butyl)aminocarbonyl, benzylaminocarbonyl, thiazolidin-1-ylcarbonyl, piperazin-1-yl-carbonyl, piperidin-1-ylcarbonyl, azetidin-1-ylcarbonyl, homopiperdin-1-ylcarbonyl, pyrimidin-2-ylaminocarbonyl, 4-methylpiperazin-1-ylcarbonyl, 4-methylpyrimidin-2-ylaminocarbonyl, pyrimidin-4-ylaminocarbonyl, pyrazin-2-ylaminocarbonyl, imidazol-2-ylaminocarbonyl.

37. (Amended) The compound of Claim 31 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is piperidin-1-ylcarbonyl, azetidin-1-ylcarbonyl, ethylaminocarbonyl, phenylaminocarbonyl, pyrimidin-2-ylaminocarbonyl, or thiazol-2-ylaminocarbonyl[;] and the stereochemistry at the C2 carbon atom of the pyrrolidine ring[, i.e., carbon carrying the R_7 group] is (*S*).

38. (Amended) The compound of Claim 31 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is -C(=O)OR_{14} where R_{14} is hydrogen or –(C_1-C_{12}) alkyl, alkoxy, aryl, or heteroaryl.

39. (Amended) The compound of Claim 31 wherein [the



group is a group of formula:



wherein:

n is 1; and]

R_7 is $-C(=O)OR_{14}$ where R_{14} is alkyl[;] and the stereochemistry at the C_2 carbon atom of the pyrrolidine ring is (*S*).

40. (Amended) The compound of any one of Claims [Claim] 32-38 wherein R_3 is *n*-butyl.

41. (Amended) The compound of any one of Claims [Claim] 13-19 wherein R_2 and R_4 are hydrogen.

46. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of Claims 1-19, 28-39, and 45 [Claims 1-45] and a pharmaceutically acceptable excipient.

47. (Amended) A method of treatment of a disease in a mammal treatable by administration of a peptidyl deformylase inhibitor which method comprises administration of a pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of Claims 1-19, 28-39, and 45 [Claims 1-45] and a pharmaceutically acceptable excipient.